Intervention Review

You have free access to this content

Vaccines for preventing influenza in healthy adults

  1. Vittorio Demicheli1,*,
  2. Tom Jefferson2,
  3. Lubna A Al-Ansary3,
  4. Eliana Ferroni4,
  5. Alessandro Rivetti1,
  6. Carlo Di Pietrantonj5

Editorial Group: Cochrane Acute Respiratory Infections Group

Published Online: 13 MAR 2014

Assessed as up-to-date: 24 MAY 2013

DOI: 10.1002/14651858.CD001269.pub5


How to Cite

Demicheli V, Jefferson T, Al-Ansary LA, Ferroni E, Rivetti A, Di Pietrantonj C. Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews 2014, Issue 3. Art. No.: CD001269. DOI: 10.1002/14651858.CD001269.pub5.

Author Information

  1. 1

    Azienda Sanitaria Locale ASL AL, Servizio Regionale di Riferimento per l'Epidemiologia, SSEpi-SeREMI - Cochrane Vaccines Field, Alessandria, Piemonte, Italy

  2. 2

    The Cochrane Collaboration, Roma, Italy

  3. 3

    College of Medicine, King Saud University, Department of Family and Community Medicine, Riyadh, Saudi Arabia

  4. 4

    Lazio Regional Health Service, Department of Epidemiology, Rome, Italy

  5. 5

    Local Health Unit Alessandria- ASL AL, Regional Epidemiology Unit SeREMI- Cochrane Vaccines Field, Alessandria, Alessandria, Italy

*Vittorio Demicheli, Servizio Regionale di Riferimento per l'Epidemiologia, SSEpi-SeREMI - Cochrane Vaccines Field, Azienda Sanitaria Locale ASL AL, Via Venezia 6, Alessandria, Piemonte, 15121, Italy. vdemicheli@aslal.it. vittoriodemicheli@libero.it.

Publication History

  1. Publication Status: Edited (no change to conclusions), comment added to review
  2. Published Online: 13 MAR 2014

SEARCH

[Figure 1]
Figure 1. Study flow diagram
[Figure 2]
Figure 2. 'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 3]
Figure 3. 'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Inactivated parenteral vaccine versus placebo or 'do nothing', Outcome 1 Influenza-like illness.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Inactivated parenteral vaccine versus placebo or 'do nothing', Outcome 2 Influenza.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Inactivated parenteral vaccine versus placebo or 'do nothing', Outcome 3 Physician visits.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Inactivated parenteral vaccine versus placebo or 'do nothing', Outcome 4 Days ill.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Inactivated parenteral vaccine versus placebo or 'do nothing', Outcome 5 Times any drugs were prescribed.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Inactivated parenteral vaccine versus placebo or 'do nothing', Outcome 6 Times antibiotic was prescribed.
[Analysis 1.7]
Analysis 1.7. Comparison 1 Inactivated parenteral vaccine versus placebo or 'do nothing', Outcome 7 Working days lost.
[Analysis 1.8]
Analysis 1.8. Comparison 1 Inactivated parenteral vaccine versus placebo or 'do nothing', Outcome 8 Hospitalisations.
[Analysis 1.9]
Analysis 1.9. Comparison 1 Inactivated parenteral vaccine versus placebo or 'do nothing', Outcome 9 Clinical cases (clinically defined without clear definition).
[Analysis 1.10]
Analysis 1.10. Comparison 1 Inactivated parenteral vaccine versus placebo or 'do nothing', Outcome 10 Local harms.
[Analysis 1.11]
Analysis 1.11. Comparison 1 Inactivated parenteral vaccine versus placebo or 'do nothing', Outcome 11 Systemic harms.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Live aerosol vaccine versus placebo or 'do nothing', Outcome 1 Influenza-like illness.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Live aerosol vaccine versus placebo or 'do nothing', Outcome 2 Influenza.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Live aerosol vaccine versus placebo or 'do nothing', Outcome 3 Influenza cases (clinically defined without clear definition).
[Analysis 2.4]
Analysis 2.4. Comparison 2 Live aerosol vaccine versus placebo or 'do nothing', Outcome 4 Local harms.
[Analysis 2.5]
Analysis 2.5. Comparison 2 Live aerosol vaccine versus placebo or 'do nothing', Outcome 5 Systemic harms.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Inactivated aerosol vaccine versus placebo or 'do nothing', Outcome 1 Influenza.
[Analysis 3.2]
Analysis 3.2. Comparison 3 Inactivated aerosol vaccine versus placebo or 'do nothing', Outcome 2 Local harms.
[Analysis 3.3]
Analysis 3.3. Comparison 3 Inactivated aerosol vaccine versus placebo or 'do nothing', Outcome 3 Systemic harms.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Inactivated parenteral vaccine versus placebo - cohort studies, Outcome 1 Seasonal inactivated vaccine effectiveness in mothers - pregnant women.
[Analysis 4.2]
Analysis 4.2. Comparison 4 Inactivated parenteral vaccine versus placebo - cohort studies, Outcome 2 Seasonal inactivated vaccine effectiveness in newborns - pregnant women.
[Analysis 4.3]
Analysis 4.3. Comparison 4 Inactivated parenteral vaccine versus placebo - cohort studies, Outcome 3 Seasonal inactivated vaccine effectiveness in newborns - pregnant women.
[Analysis 4.4]
Analysis 4.4. Comparison 4 Inactivated parenteral vaccine versus placebo - cohort studies, Outcome 4 H1N1 vaccine - safety - pregnancy-related outcomes - pregnant women.
[Analysis 4.5]
Analysis 4.5. Comparison 4 Inactivated parenteral vaccine versus placebo - cohort studies, Outcome 5 Seasonal vaccine - safety - pregnancy-related outcomes - pregnant women.
[Analysis 5.1]
Analysis 5.1. Comparison 5 Inactivated parenteral vaccine versus placebo - case-control, Outcome 1 Effectiveness in newborns - pregnant women (adjusted data).
[Analysis 5.2]
Analysis 5.2. Comparison 5 Inactivated parenteral vaccine versus placebo - case-control, Outcome 2 Seasonal vaccine safety - pregnancy-related outcomes (adjusted data).
[Analysis 6.1]
Analysis 6.1. Comparison 6 Serious adverse events - Guillain-Barré syndrome - cohort studies, Outcome 1 Seasonal influenza vaccination and Guillain-Barré syndrome.
[Analysis 7.1]
Analysis 7.1. Comparison 7 Serious adverse events - Guillain-Barré syndrome - case-control, Outcome 1 2009 to 2010 A/H1N1 - general population (unadjusted data).
[Analysis 7.2]
Analysis 7.2. Comparison 7 Serious adverse events - Guillain-Barré syndrome - case-control, Outcome 2 2009 to 2010 A/H1N1 - general population (adjusted data).
[Analysis 7.3]
Analysis 7.3. Comparison 7 Serious adverse events - Guillain-Barré syndrome - case-control, Outcome 3 Seasonal influenza vaccination general population (adjusted data).
[Analysis 8.1]
Analysis 8.1. Comparison 8 Serious adverse events - demyelinating diseases (multiple sclerosis, optic neuritis) - cohort studies, Outcome 1 Influenza vaccination (seasonal) - demyelinating diseases (unadjusted data).
[Analysis 8.2]
Analysis 8.2. Comparison 8 Serious adverse events - demyelinating diseases (multiple sclerosis, optic neuritis) - cohort studies, Outcome 2 Influenza vaccination (H1N1) - demyelinating diseases (unadjusted).
[Analysis 9.1]
Analysis 9.1. Comparison 9 Serious adverse events - demyelinating diseases (multiple sclerosis, optic neuritis) - case-control studies, Outcome 1 Influenza vaccination (seasonal) - general population - demyelinating diseases (unadjusted data).
[Analysis 9.2]
Analysis 9.2. Comparison 9 Serious adverse events - demyelinating diseases (multiple sclerosis, optic neuritis) - case-control studies, Outcome 2 Influenza vaccination (seasonal) - general population - multiple sclerosis (adjusted data).
[Analysis 9.3]
Analysis 9.3. Comparison 9 Serious adverse events - demyelinating diseases (multiple sclerosis, optic neuritis) - case-control studies, Outcome 3 Influenza vaccination (seasonal) - general population - optic neuritis (adjusted data).
[Analysis 10.1]
Analysis 10.1. Comparison 10 Serious adverse events - immune thrombocytopaenic purpura - cohort studies, Outcome 1 Seasonal influenza vaccine - HR (adjusted data).
[Analysis 10.2]
Analysis 10.2. Comparison 10 Serious adverse events - immune thrombocytopaenic purpura - cohort studies, Outcome 2 Seasonal influenza vaccine (unadjusted data).
[Analysis 11.1]
Analysis 11.1. Comparison 11 Serious adverse events - immune thrombocytopaenic purpura - case-control studies, Outcome 1 Seasonal influenza vaccine - general population (adjusted data).
[Analysis 11.2]
Analysis 11.2. Comparison 11 Serious adverse events - immune thrombocytopaenic purpura - case-control studies, Outcome 2 Seasonal influenza vaccine - general population (unadjusted data).
[Analysis 12.1]
Analysis 12.1. Comparison 12 1968 to 1969 pandemic: inactivated polyvalent parenteral vaccine versus placebo, Outcome 1 Influenza-like illness.
[Analysis 12.2]
Analysis 12.2. Comparison 12 1968 to 1969 pandemic: inactivated polyvalent parenteral vaccine versus placebo, Outcome 2 Influenza.
[Analysis 12.3]
Analysis 12.3. Comparison 12 1968 to 1969 pandemic: inactivated polyvalent parenteral vaccine versus placebo, Outcome 3 Hospitalisations.
[Analysis 12.4]
Analysis 12.4. Comparison 12 1968 to 1969 pandemic: inactivated polyvalent parenteral vaccine versus placebo, Outcome 4 Pneumonia.
[Analysis 13.1]
Analysis 13.1. Comparison 13 1968 to 1969 pandemic: inactivated monovalent parenteral vaccine versus placebo, Outcome 1 Influenza-like illness.
[Analysis 13.2]
Analysis 13.2. Comparison 13 1968 to 1969 pandemic: inactivated monovalent parenteral vaccine versus placebo, Outcome 2 Influenza.
[Analysis 13.3]
Analysis 13.3. Comparison 13 1968 to 1969 pandemic: inactivated monovalent parenteral vaccine versus placebo, Outcome 3 Hospitalisations.
[Analysis 13.4]
Analysis 13.4. Comparison 13 1968 to 1969 pandemic: inactivated monovalent parenteral vaccine versus placebo, Outcome 4 Pneumonia.
[Analysis 13.5]
Analysis 13.5. Comparison 13 1968 to 1969 pandemic: inactivated monovalent parenteral vaccine versus placebo, Outcome 5 Working days lost.
[Analysis 13.6]
Analysis 13.6. Comparison 13 1968 to 1969 pandemic: inactivated monovalent parenteral vaccine versus placebo, Outcome 6 Days ill.
[Analysis 14.1]
Analysis 14.1. Comparison 14 1968 to 1969 pandemic: inactivated polyvalent aerosol vaccine versus placebo, Outcome 1 Influenza-like illness.
[Analysis 15.1]
Analysis 15.1. Comparison 15 1968 to 1969 pandemic: inactivated monovalent aerosol vaccine versus placebo, Outcome 1 Influenza-like illness.
[Analysis 16.1]
Analysis 16.1. Comparison 16 1968 to 1969 pandemic: live aerosol vaccine versus placebo, Outcome 1 Influenza cases (clinically defined without clear definition).
[Analysis 16.2]
Analysis 16.2. Comparison 16 1968 to 1969 pandemic: live aerosol vaccine versus placebo, Outcome 2 Complications (bronchitis, otitis, pneumonia).